Inactivated antithrombins as fondaparinux antidotes: a promising alternative to haemostatic agents as assessed in vitro in a thrombin-generation assay

Summary

In the absence of specific antidote to fondaparinux, two modified forms of antithrombin (AT), one recombinant inactive (ri-AT) and the other chemically inactivated (chi-AT), were designed to antagonise AT-mediated anticoagulants, e. g. heparins or fondaparinux. These inactive ATs were previously proven to effectively neutralise anticoagulant activity associated with heparin derivatives in vitro and in vivo, as assessed by direct measurement of anti-FXa activity. This study was undertaken to evaluate in vitro the effectivity of inactive ATs to reverse anticoagulation by heparin derivatives and to compare them with non-specific fondaparinux reversal agents, like recombinant-activated factor VII (rFVIIa) or activated prothrombin-complex concentrate (aPCC), in a thrombin-generation assay (TGA). Addition of fondaparinux (3 μg/ml) to normal plasma inhibited thrombin generation by prolonging lag time (LT) as much as 244 % and lowering endogenous thrombin potential (ETP) to 17 % of their control (normal plasma) values. Fondaparinux-anticoagulant activity was reversed by ri-AT and chi-AT, as reflected by the corrections of LT up to 117 % and 114 % of its control value, and ETP recovery to 78 % and 63 %, respectively. Unlike ri-AT that had no effect on thrombin generation in normal plasma, chi-AT retained anticoagulant activity that minimises its reversal capacity. However, both ATs were more effective than rFVIIa or aPCC at neutralising fondaparinux and, unlike non-specific antidotes, inactive ATs specifically reversed AT-mediated anticoagulant activities, as suggested by their absence of procoagulant activity in anticoagulant-free plasma.

Keywords

Antithrombin - fondaparinux - heparin - reversal - thrombin-generation assay

^* D. Borgel and EP. Bianchini contributed equally to this work.

• References

• 1 Nagler M, Haslauer M, Wuillemin WA.. Fondaparinux – data on efficacy and safety in special situations. Thromb Res 2012; 129: 407-417.
• 2 Crowther MA, Warkentin TE.. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood 2008; 111: 4871-4879.
• 3 van Veen JJ, Maclean RM, Hampton KK. et al. Protamine reversal of low molecular weight heparin: clinically effective?. Blood Coagul Fibrinolysis 2011; 22: 565-570.
• 4 Hirsh J, Bauer KA, Donati MB. et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (Suppl) 141S-159S.
• 5 Young G, Yonekawa KE, Nakagawa PA. et al. Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography. Blood Coagul Fibrinolysis 2007; 18: 547-553.
• 6 Lisman T, Bijsterveld NR, Adelmeijer J. et al. Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux. J Thromb Haemost 2003; 1: 2368-2373.
• 7 Desmurs-Clavel H, Huchon C, Chatard B. et al. Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aPCC and PCC. Thromb Res 2009; 123: 796-798.
• 8 Gerotziafas GT, Depasse F, Chakroun T. et al. Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood. Thromb Haemost 2004; 91: 531-537.
• 9 Corbonnois G, Martin M, Hacquard M. et al. Fondaparinux reversal with activated prothrombin complex concentrate in anesthetised bleeding rats. Thromb Haemost 2013; 109: 560-563.
• 10 Bijsterveld NR, Moons AH, Boekholdt SM. et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002; 106: 2550-2554.
• 11 Kenet G, Walden R, Eldad A. et al. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 1999; 354: 1879.
• 12 Huvers F, Slappendel R, Benraad B. et al. Treatment of postoperative bleeding after fondaparinux with rFVIIa and tranexamic acid. Neth J Med 2005; 63: 184-186.
• 13 Luporsi P, Chopard R, Janin S. et al. Use of recombinant factor VIIa (Novo-Seven*) in 8 patients with ongoing life-threatening bleeding treated with fondaparinux. Acute Card Care 2011; 13: 93-98.
• 14 Makris M, Van Veen JJ, Tait CR. et al. Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematol 2013; 160: 35-46.
• 15 Levi M, Levy JH, Andersen HF. et al. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010; 363: 1791-1800.
• 16 Wojcik C, Schymik ML, Cure EG.. Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy. Int J Emerg Med 2009; 2: 217-225.
• 17 Bianchini EP, Fazavana J, Picard V. et al. Development of a recombinant antithrombin variant as a potent antidote to fondaparinux and other heparin derivatives. Blood 2011; 117: 2054-2060.
• 18 Fazavana J, Bianchini EP, Saller F. et al. A chemically-modified inactive antithrombin as a potent antagonist of fondaparinux and heparin anticoagulant activity. J Thromb Haemost 2013; 11: 1128-1136.
• 19 Ersdal-Badju E, Lu A, Peng X. et al. Elimination of glycosylation heterogeneity affecting heparin affinity of recombinant human antithrombin III by expression of a beta-like variant in baculovirus-infected insect cells. Biochem J 1995; 310: 323-330.
• 20 Pike RN, Potempa J, Skinner R. et al. Heparin-dependent modification of the reactive center arginine of antithrombin and consequent increase in heparin binding affinity. J Biol Chem 1997; 272: 19652-19655.
• 21 Gatt A, van Veen JJ, Woolley AM. et al. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro . Thromb Haemost 2008; 100: 350-355.
• 22 Castellone DD, Van Cott EM.. Laboratory monitoring of new anticoagulants. Am J Hematol 2010; 85: 185-187.
• 23 Klitgaard T, Nielsen TG.. Overview of the human pharmacokinetics of recombinant activated factor VII. Br J Clin Pharmacol 2008; 65: 3-11.
• 24 Chu AJ, Wang ZG, Raicu M. et al. Protamine inhibits tissue factor-initiated extrinsic coagulation. Br J Haematol 2001; 115: 392-399.
• 25 Ni Ainle F, Preston RJ, Jenkins PV. et al. Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation. Blood 2009; 114: 1658-1665.
• 26 Monroe DM, Hoffman M, Oliver JA. et al. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99: 542-547.
• 27 Crowther MA, Berry LR, Monagle PT. et al. Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol 2002; 116: 178-186.
• 28 McLaughlin KE, Dunning J.. In patients post cardiac surgery do high doses of protamine cause increased bleeding?. Interact Cardiovasc Thorac Surg 2003; 2: 424-426.
• 29 Butterworth J, Lin YA, Prielipp RC. et al. Rapid disappearance of protamine in adults undergoing cardiac operation with cardiopulmonary bypass. Ann Thorac Surg 2002; 74: 1589-1595.
• 30 Collen D, Schetz J, de Cock F. et al. Metabolism of antithrombin III (heparin cofactor) in man: effects of venous thrombosis and of heparin administration. Eur J Clin Invest 1977; 7: 27-35.
• 31 U. S. Food and Drug Administration. Summary Basis for Regulatory Action – Atryn. Available at: http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm134048.htm Accessed November 27, 2015
• 32 Linkins LA, Dans AL, Moores LK. et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl) e495S-e4530S.
• 33 Lu G, DeGuzman FR, Hollenbach SJ. et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013; 19: 446-451.
• 34 Siegal DM, Curnutte JT, Connolly SJ. et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015; 373: 2413-2424.